Androgen Receptor-Directed Molecular Conjugates for Targeting Prostate Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Androgen Receptor-Directed Molecular Conjugates for Targeting Prostate Cancer
Authors
Keywords
-
Journal
Frontiers in Chemistry
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-05-28
DOI
10.3389/fchem.2019.00369
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Design, synthesis, and evaluation of the antiproliferative activity of hydantoin-derived antiandrogen-genistein conjugates
- (2018) Alex George et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Androgen receptor (AR) degradation enhancer ASC-J9 ® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth
- (2018) Max A. Cheng et al. CANCER LETTERS
- ASC-J9 ® suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3
- (2018) WanYing Lin et al. CANCER LETTERS
- A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
- (2018) Michael T. Schweizer et al. PLoS One
- Emerging Therapies in Metastatic Prostate Cancer
- (2018) Daniel W. Sonnenburg et al. Current Oncology Reports
- Molecular and cellular mechanisms of castration resistant prostate cancer (Review)
- (2018) Yiqiao Huang et al. Oncology Letters
- Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9 led to increase docetaxel sensitivity via suppressing the p21 expression
- (2018) Jie Luo et al. CANCER LETTERS
- Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer
- (2018) Navid Sobhani et al. INVESTIGATIONAL NEW DRUGS
- Alternative splicing in prostate cancer
- (2018) Alec Paschalis et al. Nature Reviews Clinical Oncology
- Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain
- (2018) N. G. R. Dayan Elshan et al. MEDICINAL RESEARCH REVIEWS
- Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 ® to Suppress Enzalutamide-resistant Prostate Cancer Progression
- (2017) Ronghao Wang et al. EUROPEAN UROLOGY
- 1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment
- (2017) Claudia Ferroni et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
- (2017) Norihito Shibata et al. JOURNAL OF MEDICINAL CHEMISTRY
- Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
- (2017) Ian Churcher JOURNAL OF MEDICINAL CHEMISTRY
- Antagonizing the Androgen Receptor with a Biomimetic Acyltransferase
- (2016) Yuchen Zhang et al. ACS Chemical Biology
- Small-Molecule PROTACS: New Approaches to Protein Degradation
- (2016) Momar Toure et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- ASC-J9® suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L
- (2016) Ronghao Wang et al. CANCER LETTERS
- Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells
- (2016) Y. Wang et al. CANCER RESEARCH
- A photodynamic bifunctional conjugate for prostate cancer: an in vitro mechanistic study
- (2016) Valentina Rapozzi et al. INVESTIGATIONAL NEW DRUGS
- Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells
- (2016) Simeng Wen et al. MOLECULAR CARCINOGENESIS
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer
- (2016) Chengfei Liu et al. Oncotarget
- Epigenetic modulators as therapeutic targets in prostate cancer
- (2016) Inês Graça et al. Clinical Epigenetics
- Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging
- (2015) Jeffrey L. Gustafson et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Androgen Receptor Targeted Conjugate for Bimodal Photodynamic Therapy of Prostate Cancer in Vitro
- (2015) Valentina Rapozzi et al. BIOCONJUGATE CHEMISTRY
- AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies
- (2015) A. Omlin et al. INVESTIGATIONAL NEW DRUGS
- ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors
- (2015) Shinichi Yamashita et al. NEOPLASIA
- Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells
- (2014) Jeffrey Cummings et al. BMC CANCER
- Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2014) C. Liu et al. CLINICAL CANCER RESEARCH
- A New Avenue toward Androgen Receptor Pan-antagonists: C2 Sterically Hindered Substitution of Hydroxy-propanamides
- (2014) Andrea Guerrini et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors
- (2013) Berkley E. Gryder et al. ACS Chemical Biology
- Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer
- (2013) Robert H. Bradbury et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Infiltrating Macrophages Promote Prostate Tumorigenesis via Modulating Androgen Receptor-Mediated CCL4-STAT3 Signaling
- (2013) L.-Y. Fang et al. CANCER RESEARCH
- AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo
- (2013) S. A. Loddick et al. MOLECULAR CANCER THERAPEUTICS
- Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling
- (2013) T-H Lin et al. Cell Death & Disease
- Increased Infiltrated Macrophages in Benign Prostatic Hyperplasia (BPH)
- (2012) Xiaohai Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting Androgen Receptor Leads to Suppression of Prostate Cancer via Induction of Autophagy
- (2012) Qi Jiang et al. JOURNAL OF UROLOGY
- Design, synthesis and biological evaluation of nuclear receptor-degradation inducers
- (2011) Yukihiro Itoh et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer
- (2011) Robert H. Bradbury et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- An androgenic steroid delivery vector that imparts activity to a non-conventional platinum(ii) metallo-drug
- (2010) Martin Huxley et al. DALTON TRANSACTIONS
- Conjugation of testosterone modifies the interaction of mono-functional cationic platinum(ii) complexes with DNA, causing significant alterations to the DNA helix
- (2010) Carlos Sanchez-Cano et al. DALTON TRANSACTIONS
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
- (2008) Ashley R. Schneekloth et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started